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Summary
Background: Variations in emergency care quality for alcohol-related liver disease 
(ARLD) have been highlighted.
Aim: To determine whether introduction of a regional quality improvement (QI) pro-
gramme was associated with a reduction in potentially avoidable inpatient mortality.
Method: Retrospective observational cohort study using hospital administrative 
data spanning a 1-year period before (2014/2015) and 3 years after a QI initiative at 
seven acute hospitals in North West England. The intervention included serial audit 
of a bundle of process metrics. An algorithm was developed to identify index (“first”) 
emergency admissions for ARLD (n = 3887). We created a standardised mortality 
ratio (SMR) to compare relative mortality and regression models to examine risk-
adjusted odds of death.
Results: In 2014/2015, three of seven hospitals had an SMR above the upper control 
limit (“outliers”). Adjusted odds of death for patients admitted to outlier hospitals was 
higher than non-outliers (OR 2.13, 95% CI 1.32-3.44, P = 0.002). Following the QI 
programme there was a step-wise reduction in outliers (none in 2017/2018). Odds of 
death was 67% lower in 2017/2018 compared to 2014/2015 at original outlier hos-
pitals, but unchanged at other hospitals. Process audit performance of outliers was 
worse than non-outliers at baseline, but improved after intervention.
Conclusions: There was a reduction in unexplained variation in hospital mortality 
following the QI intervention. This challenges the pessimism that is prevalent for 
achieving better outcomes for patients with ARLD. Notwithstanding the limitations 
of an uncontrolled observational study, these data provide hope that co-ordinated 
efforts to drive adoption of evidence-based practice can save lives.
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1  | INTRODUC TION
Alcohol-related liver disease (ARLD) typically presents late and often 
with fatal complications. In the UK it is estimated that up to 75% 
of fatal liver cirrhosis is undetected before a patient’s first hospi-
talisation.1,2 Nevertheless, early inpatient intervention with evi-
dence-based treatments has the potential to save lives.3 However, 
variation in the provision, quality and consistency of inpatient care 
has been highlighted in several countries. In the UK in 2013, a re-
port entitled “Measuring the Units” from the National Confidential 
Enquiry into Patient Outcome and Death (NCEPOD) showed subop-
timal care for patients dying during a hospitalisation for ARLD.4 Only 
47% of cases were judged to have received “good care” in hospital 
and potentially avoidable deaths were identified. A year later, the 
Lancet Commission highlighted wide variation in inpatient mortality, 
describing a “postcode lottery of liver services”2 and a parliamentary 
group raised “grave concerns” about patchy provision of high-quality 
specialist care.5 A follow-up report included a comparative analysis 
of administrative data for in-hospital mortality for non-elective ad-
missions for “liver disease” across 134 English hospitals (2014-2018), 
suggesting more than twofold variation both in crude mortality 
(range: 6%-16%) and standardised mortality ratio (SMR ranging from 
approximately 60-140) across providers.6 Specific data for ARLD 
were not presented. Evidence of inconsistent acute care for patients 
admitted to US hospitals with decompensated liver disease were re-
ported in 20127 and 2014.8
There has been progress in defining candidate process measures 
to help identify variations in key aspects of care and support quality 
improvement (QI).9–12 However, no real-world evidence has emerged 
for QI programmes leading to reductions in avoidable hospital mor-
tality. In 2016, Dyson et al reported an initiative for decompensated 
cirrhosis from three English hospitals.13 Responding to NCEPOD rec-
ommendations, the authors introduced a “liver bundle” to promote 
best practice and undertook audits of care before and after efforts 
to implement it. Alcohol was the underlying cause of cirrhosis in 85% 
of cases. After roll-out, the bundle was completed in 59% of 136 pa-
tients and these cases had significantly higher rates of early diagnos-
tic ascitic tap, antibiotic prescribing and documentation of alcohol 
consumption. Overall mortality was 15%, but the study was unable 
to detect significant reduction in death rate over time, nor demon-
strate a lower rate of mortality for patients with a completed bundle. 
An editorial expressed frustration that despite a successful effort to 
implement a policy promoting early delivery of evidence-based care, 
evidence for improvement in the “hard end-point” of survival was 
lacking.14 The commentary suggested that future evaluations of QI 
interventions needed to include centres where in-hospital mortality 
was “unusually high.”
The North West region of England has one of the country’s 
highest rates of alcohol-specific deaths and ARLD is the dominant 
cause.15 In early 2015, the Advancing Quality Alliance launched a 
regional QI programme focused on improving emergency hospital 
care for ARLD. We report a retrospective analysis of time trends 
in inpatient mortality across seven participating hospitals, using 
independent administrative data to examine whether the pro-
gramme was associated with a reduction in unwarranted variation in 
deaths during emergency admission for ARLD. This work was part of 
the North West Coast Connected Health Cities programme, a pub-
licly funded regional health informatics initiative aimed at enhanc-




This was a retrospective observational cohort study using routinely 
collected, anonymised administrative data for the period 2014/2015 
to 2017/2018.
2.2 | Setting
Seven acute hospitals in the North West region of England that par-
ticipated in a regional QI programme.
2.3 | The Advancing Quality intervention
Advancing Quality (AQ) is a care programme operated by the 
Advancing Quality Alliance (AQuA) which delivers a range of services 
to NHS healthcare organisations across the North West of England.17 
The programme offers members a structured approach to embed-
ding evidence-based care with the aims of improving health outcomes 
while reducing unwarranted variation in the care of highly prevalent 
conditions. Prior to launch of each programme, a local Clinical Expert 
Group reviews evidence and identifies a set of condition-specific in-
terventions known to improve outcomes along with a set of process 
measures to allow benchmarking of care (“AQ measures”). The AQ pro-
gramme includes continuous audit of samples of admissions to moni-
tor hospital-level performance against AQ measures, with transparent 
monthly reporting and a series of regional QI meetings of participat-
ing teams. The QI initiative was also supported by an optional finan-
cial incentive scheme (Commissioning for Quality & Innovation, CQIN) 
during 2015/2016 to 2016/2017, whereby local service commission-
ers could assign a small proportion of contracted payments to acute 
hospitals for participation.18 The programme for ARLD was launched 
in 2015, with an original set of 11 AQ measures collected.19 The meas-
ures focused on the early detection and management of complications 
linked to in-hospital mortality (eg spontaneous bacterial peritonitis and 
variceal bleeding) as well as triage to correct ward and early special-
ist hepatology input (Table 5). Review of AQ measures by the Clinical 
Expert Group in 2017/2018 resulted in refinement of some definitions, 
merger or retirement of selected process measures (to simplify data 
collection or remove metrics that were no longer required), resulting in 
seven process metrics.
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2.4 | Data sources, information 
governance and ethics
Complete administrative data were available for seven participating 
hospitals for the period 2013/2014 to 2017/2018. The dataset is 
equivalent to Hospital Episode Statistics, as previously described.20 
We focused our analysis on admissions in the year before the AQ 
programme was launched (2014/2015) and three consecutive fis-
cal years after the intervention (2015/2016 to 2017/2018). Data for 
2013/2014 were used as screening period to enable identification 
of index (“first”) admissions for ARLD (see cohort selection below). 
This work formed part of a service evaluation and improvement pro-
gramme and made use of anonymised administrative data with ap-
proval from NHS Digital, hence ethical approval was not required. 
Benchmarking reports based on our analyses of administrative data 
were shared with hospital teams in August 2019.
Aggregated hospital-level information relating to serial local 
audits was provided by AQuA, including data collected during the 
first 3 months of the AQ programme when teams received their first 
(baseline) reports of audit performance, and data from the latest 
available comparable 3-month period within the time frame of our 
analysis of administrative data (January-March 2018).
2.5 | Cohort selection
2.5.1 | Development and validation of diagnostic 
coding algorithm
The standard approach for identifying admissions within admin-
istrative data is to focus exclusively on the primary (principal) dis-
charge diagnosis code. However, ARLD is a complex condition and 
can present with a spectrum of symptoms, signs, specific disease 
complications and with other co-existing alcohol-related disorders. 
Inadequate identification of liver-related admissions based on pri-
mary diagnosis alone has been reported.21 Hence, we needed to de-
velop a better method for identifying cohorts of people with ARLD 
and their relevant emergency admissions from administrative data. 
Each care episode contains up to 23 diagnostic codes, classified ac-
cording to version 10 of the International Classification of Diseases 
(ICD-10).
Using the regional dataset for all-cause admissions, we set out 
to define patterns of diagnostic codes consistent with acute pre-
sentations of ARLD (Table 1). First, we flagged admissions with any 
of the six specific codes for ARLD recorded as primary diagnosis 
(Table S1)—referred to as ARLD-Primary admissions and reflecting 
the standard approach. Next, we extracted admissions where such 
codes appeared in a nonprimary position and created frequency ta-
bles of the primary diagnoses recorded for those admissions. Two 
clinicians reviewed the tables independently, selecting primary 
codes compatible with emergency presentations of ARLD. Any dis-
crepancies were resolved by informal consensus. This resulted in 
one code list for “symptoms, signs or complications” of ARLD (eg 
jaundice, ascites, oesophageal varices, acute kidney injury, infec-
tions/sepsis, encephalopathy; Table S2) and another for “other al-
cohol-specific conditions” (eg acute alcohol withdrawal or alcoholic 
gastritis; Table S3). Primary codes were rejected when judged to in-
dicate that ARLD was not the main reason for admission (eg chronic 
obstructive airways disease).
We also identified other categories of admission where a code 
for nonspecific liver disease (eg other and unspecified cirrhosis of 
the liver; Table S4) co-existed with a code for an alcohol-specific 
condition—thereby suggesting the liver disease was alcohol related. 
Using the clinician-generated list for symptoms, signs and complica-
tions, we defined which of these admissions were also eligible for 
inclusion. An algorithmic procedure was created to screen the data-
set to identify admissions with any of the permitted coding combi-
nations, referred to collectively as ARLD-Algorithm admissions. This 
included ARLD-Primary admissions plus the extra admissions identi-
fied from alternative coding patterns (ARLD-Uplift).
Algorithm performance was evaluated at one hospital as part of 
an audit of care by two independent clinician observers (BS and LA), 
each reviewing a series of consecutive patients (n = 49 and n = 48 
respectively) who had been referred to alcohol services during an 
emergency admission. Review of manual and electronic records 
established whether or not the admission was related to acute 
management of ARLD with the two reviewers blinded to discharge 
TA B L E  1   Summary of diagnostic coding algorithm to identify 
admissions for alcohol-related liver disease (ARLD) within the 
administrative dataset. Each care episode in the dataset contains up 
to 23 diagnostic codes assigned by clinical coders after discharge, 
using the International Classification of Diseases 10th Revision 
(ICD-10) system. See Supporting information for full code lists.
The list of ICD-10 codes must conform to one of four patterns:
1. ARLD-specific codea  recorded as primary diagnosis 
(ARLD-Primary)
2. ARLD-specific code recorded as a secondary diagnosis
All higher order diagnoses must be either:
(A) Symptom, sign or complicationb , or
(B) Other alcohol-specific diagnosisc 
3. Nonspecific liver disease coded  recorded as a primary diagnosis
Lower order diagnoses must include one alcohol-specific diagnosis
4. Nonspecific liver disease recorded as a secondary diagnosis
All higher order diagnoses must be either:
(A) Symptom, sign or complication, or
(B) Other alcohol-specific diagnosis (at least one must be recorded)
aSix specific codes for alcohol-related liver disease (see Table S1). 
bCodes for jaundice, ascites, varices, acute kidney injury, 
encephalopathy and other relevant diagnoses suggesting admission for 
ARLD complications (see Table S2). 
cCodes for other alcohol-specific conditions such as alcohol 
intoxication, withdrawal and organ-specific disorders (eg alcoholic 
gastritis; see Table S3). 
dCodes for liver disease without specific aetiology (eg cirrhosis, 
unspecified; see Table S4). 
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coding. Thirteen ARLD admissions were identified among the 97 
cases. Discharge codes were then extracted and admissions clas-
sified by the primary and algorithm methods. We confirmed that 
ARLD-Primary approach had excellent specificity (100%) but poor 
sensitivity for detecting all relevant liver-related admissions (only 
61.5%), whereas the algorithm had much better sensitivity (92.3%) 
while retaining high specificity (91.7%).
2.6 | Defining index admissions for ARLD
We aimed to study the outcome of emergency hospitalisation for 
ARLD by selecting a standardised starting point in the journey of 
individual patients. Hence, we focused on the first admission in any 
sequence of admissions and readmissions. We refer to these first 
admissions as index admissions. An index admission could be either 
a patient’s first unplanned admission with ARLD in the dataset, or a 
readmission with a new acute decompensation after a long admis-
sion-free interval. Using the discharge date for each ARLD spell, we 
selected only those with no preceding discharge for ARLD in the 
prior 365 days.
Index admissions are a major milestone in the patient journey—
representing a new, acute crisis for the individual patient. They 
represent a crucial point in the patient journey, an opportunity for 
co-ordinated intervention by the acute liver services and alcohol 
care team to reduce avoidable in-hospital morbidity and mortality, 
and set the patient on the path to long-term abstinence and recov-
ery. By focusing on a standardised “first” admission, rather than 
pooling admissions and readmissions, there would be a better op-
portunity to make a fair comparison of outcomes of acute inpatient 
care between hospitals. Over the 4-year period, there were 2001 
index admissions identified using primary diagnosis alone compared 
to 3887 admissions captured using the coding algorithm—an uplift 
of 1,886 index admissions with a coding sequence compatible with 
ARLD (Figure 1A).
2.7 | Primary outcome
The primary outcome was death during an index admission for 
ARLD. This was established from the discharge method variable in 
the dataset which records death in hospital.20
2.8 | Case mix variables
We extracted case mix variables for age, sex, co-morbidity and dep-
rivation status of place of residence as previously described.20 For 
co-morbidity we used Charlson co-morbidity Index as defined in 
the national Summary Hospital-level Mortality Index (SHMI), using 
the categorical version.22 For category 1, the index is 0, category 2 
has scores of 1-5 and category 3 is 6 and above. Deprivation status 
of place of residence was entered in our models using the Index of 
Multiple Deprivation Rank quintiles as defined at national level and 
we used quintile 5 (least deprived quintile) as the reference category 
as previously described.20
Recognising the variable presentations with specific complica-
tions of ARLD, we also created code lists for varices, ascites and 
acute kidney injury. We screened all ICD-10 codes in each episode 
of the index ARLD admissions and created binary variables for these 
clinical characteristics. Addition variables included whether the ad-
mission was a short stay (<2 days) and whether higher level or inten-
sive care was required.
2.9 | Identification of outlier hospitals prior to the 
intervention
Our first objective was to determine whether there had been unex-
plained variation in risk-adjusted mortality between hospitals prior 
to launch of the AQ programme, thereby identifying any “outliers” 
for the baseline year (2014/2015). For the purpose of institutional 
comparison and creation of funnel plots, we generated a SMR for 
each fiscal year, representing the ratio of observed (O) to expected 
(E) deaths. The SMR is calculated by multiplying the standardised 
ratio (O/E) by 100. An SMR of 100 indicates that the observed num-
ber of deaths was equal to the expected number.
Expected deaths were determined using risk-adjustment pro-
cedures as described by Spiegelhalter.23 Logistic regression mod-
els were constructed to estimate the probability of death at the 
end of each index admission within a fiscal year for each provider, 
thereby allowing expected deaths (E) to be calculated as the sum 
of those probabilities. To obtain these probabilities, we used 
stepwise binary logistic regression to determine adjusted odds 
of in-hospital death. Candidate independent variables included 
age group, sex, deprivation status, co-morbidity (Charlson score 
categories), ARLD-specific code recorded as primary diagnosis, 
disease-specific complications (varices, acute kidney injury, asci-
tes), short stay status (<2 days) and requirement for higher level 
or intensive care.
By implementing stepwise selection of variables, we iden-
tified the combination of case mix variables that were signifi-
cant predictors of in-hospital death. For this selection, we used 
conventional significance level thresholds for entering and re-
moving case mix variables from logistic regression (P < 0.05 
for entering and P > 0.10 for removing a variable) and used ro-
bust SEs to adjust for clustering of admission within patients. 
The case mix variables included in the overall logistic regres-
sion model after stepwise selection (in order of entry into the 
model based on statistical significance) were: Acute kidney in-
jury (P < 0.001); Requirement for higher level or intensive care 
(P < 0.001); ARLD-specific code recorded as primary diagnosis 
(P < 0.001); Age group categories (P < 0.001); Charlson score 
categories (P < 0.001); Ascites (P = 0.001); Short stay status 
(<2 days) (P = 0.002); Varices (P = 0.024). We compared perfor-
mance of basic adjustment models (containing only generic case 
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F I G U R E  1   (a) Comparison of 
traditional method (ARLD-Primary) and 
clinically designed algorithm (ARLD-
Algorithm) for cohort discovery of 
index admissions for alcohol-related 
liver disease (ARLD) from routine 
administrative data (pooled data for seven 
hospitals for the period 2014/2015 to 
2017/2018). The algorithmic approach 
identifies an “uplift” of 48% (ie potentially 
missed cases) with coding patterns 
compatible with an admission for 
symptoms, signs and/or complications 
of ARLD. See Table 1 for overview of 
diagnostic coding rules, and Tables S1–S4 
for code lists. (b) Geographical distribution 
of ARLD-Algorithm index admissions and 
location of seven hospitals included in 
the study. Shaded areas represent Middle 
Layer Super Output Areas of residence 
(mean population of 7200 residents per 
area). Colours represent quintiles of 
age- and sex-standardised rate of ARLD-
algorithm admissions per capita using 
pooled data for the entire 4-y period
ARLD primary
(n = 2,001, 51.5%)
ARLD uplift
(n = 1,886, 48.5%)
ARLD algorithm(A)
(B)
(n = 3,887, 100%)
Index admission rate
(standardised for age and sex)
Low
High
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mix factors) to more advanced models (using alternative sets of 
variables) by examining the proportion of variation in mortality 
explained (pseudo-R2 statistic), and then adopted the optimum 
model for risk-adjustment.
For creating funnel plots, we used the funnelcompar com-
mand in stata statistical package version 15 (which is based on 
Spiegelhalter),23 we identified whether SMR relative to the number 
of index admissions24 was within acceptable limits (i.e. within 2 SD; 
95%), between 2 and 3 SD, or beyond 3 SD (99.8%). An outlier in 
2014/2015 (baseline year) was defined as a provider where SMR was 
beyond the upper 3 SD control limit.
2.10 | Comparison of risk-adjusted mortality for the 
pre- and post-intervention periods
We generated a series of funnel plots, one for each fiscal year, to illus-
trate time trends in the degree of inter-institutional variation, as previ-
ously described.25 Having identified a group of outlier hospitals with 
“higher than expected” mortality prior to the intervention, we applied 
a categorical variable to represent all admissions to those hospitals 
throughout the observation period. This allowed risk-adjusted mor-
tality models to examine time trends in mortality risk separately for 
outlier hospitals (where unexplained mortality had been identified) and 
non-outlier hospitals (where no such signals were present at baseline).
To test the significance of time trends in adjusted odds of death, we 
used fiscal year of admission as a categorical variable and designated 
the pre-intervention year (2014/2015) as the comparator. We also ex-
plored any individual hospital “effects,” by adding a categorical variable 
to represent admission to each of the seven hospitals. This allowed us 
to test any specific associations for individual providers beyond their 
baseline grouping as outlier or non-outlier hospitals.
2.11 | Analysis of local audit data at the 
beginning and end of the observation period
We compared the locally collected audit data for performance on 
AQ process measures, pooling data for those hospitals identified 
as outliers and non-outliers for inpatient mortality for 2014/2015. 
We implemented binomial regression to compare for each clinical 
indicator the proportion of successful implementations during the 3 
month baseline period and the final comparable time period (January 
2018-March 2018).
3  | RESULTS
3.1 | Demographic and clinical characteristics
Over the 4 fiscal years, there were 3887 index emergency admis-
sions for ARLD to the seven hospitals (Table 2). The geographical 
distribution of the admissions and location of hospitals is shown 
in Figure 1B. The mean age at the time of index admission was 53 
years, with men accounting for 63%. Over half (56.8%) were resi-
dents of an area classified within the most deprived quintile for the 
country, 15.5% were in quintile 2, 11.2% in quintile 3, 9.4% in quintile 
4 and just 7.1% in quintile 5 (least deprived).
Overall, approximately one in five patients had ICD-10 codes 
consistent with acute kidney injury (21.7%), one in three had 
codes compatible with ascites (32.4%) and over one in six pa-
tients had varices (15.5%). The median length of stay was 6 days 
(IQR: 3-14). Short stays (<2 days) accounted for 14.1% of index 
admissions. There were 304 admissions that required a period 
of higher level or intensive care (7.8%), indicating severe disease 
complications.
3.2 | Deaths in hospital and case mix factors 
associated with in-hospital death
There were 534 in-hospital deaths during index admissions 
(crude mortality rate of 13.7%). Compared to those discharged 
alive, patients who died during their index admission were 
older (mean age 57.7 vs 52.8, P < 0.001), more frequently fe-
male (41.2% vs 36.3%, P = 0.030) and had more co-morbidities 
(72.5% vs 48.4% with Charlson index >5, P < 0.001), acute kidney 
injury codes (66.5% vs 14.5%, P < 0.001), ascites codes (53.6% 
vs 29.0%, P < 0.001) and requirement for intensive or higher 
level care (31.1% vs 4.1%, P < 0.001). The average deprivation 
status (mean IMD Rank) of those who died was actually some-
what higher (ie more affluent) than survivors (9529 vs 8572, 
P = 0.024). The proportion of patients with codes for varices 
was greater but not significantly different among those who died 
(16.9% vs 15.3%, P = 0.357).
3.3 | Variation in mortality between hospitals prior 
to the AQ programme and identification of outliers
We compared performance for risk-adjusted mortality (SMR) using 
funnel charts, plotting mortality vs number of index admissions. In the 
fiscal year prior to roll-out of the AQ programme (2014/2015), three 
hospitals had an SMR above the upper 3SD control limit (Figure 2A)—
suggesting special cause or unwarranted variation. Using stepwise 
logistic regression analysis, we further confirmed that patients admit-
ted to the outlier group of hospitals had an increased adjusted odds 
of death (OR 2.13, 95% CI 1.32-3.44, P = 0.002) compared to those 
admitted to the non-outlier hospitals during that year (Table 3a).
3.4 | Time trends in variation between hospitals and 
elimination of outliers
Over the observation period there was a step-wise reduction in the 
number of hospitals with an SMR lying outside the upper 3 SD funnel 
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limit in each successive fiscal year (Figure 2A-D). By 2017/2018, 
there were no outliers. Figure 3 shows adjusted mortality data for the 
individual hospitals, comparing SMR in 2014/2015 with 2017/2018.
As expected from these observations, the magnitude of variation 
in SMR between the hospitals reduced significantly over the 4 years, 
with a standard deviation of 26, 28, 19 and 12 respectively. Taken 
together, these data provide evidence for a reduction in unexplained 
or potentially “avoidable” mortality and a narrowing of variation be-
tween hospitals.
3.5 | Associations between admission year and 
odds of death according to outlier status
We further examined time trends in a series of models. Taking the 
pre-intervention year as the reference year (2014/2015), there was a 
significant association between fiscal year of admission and a reduc-
ing odds of death for patients admitted to the three outlier hospitals 
(Table 4a). Admission in 2017/2018 was associated with a 67% re-
duction in adjusted odds of death compared to the pre-intervention 
year (OR 0.33, 95% CI 0.18-0.63, P = 0.001). Hence, for hospitals 
identified as having a high SMR prior to the AQ intervention, the risk 
of death was significantly reduced over time. This suggests a reduc-
tion in “avoidable” mortality.
There was no significant association between fiscal year of 
admission and odds of death for patients admitted to the hospi-
tals that were not mortality outliers in the pre-intervention year 
(Table 4b). Hence, risk-adjusted mortality during index admissions 
was unchanged over time. This would be expected, as non-outlier 
hospitals were not identified as having “special cause” variation 
in mortality prior to the QI programme and so would have less 
TA B L E  2   Characteristics and outcome of index admissions for alcohol-related liver disease (ARLD) to seven acute NHS hospitals in the 
North West region of England. Stratified by fiscal year and survival status
Characteristica  2014/2015 2015/2016 2016/2017 2017/2018 Total Survived Died
Index admissions 957 1022 953 955 3887 3353 534
Male 585 663 593 609 2450 2136 314
61.1% 64.9% 62.2% 63.8% 63.0% 63.7% 58.8%
Age (mean) 52.3 53.4 54.0 54.1 53.4 52.7 57.7
(SD) 11.9 11.5 12.2 11.6 11.8 11.7 11.7
Deprivation (mean IMD rank) 8038 8811 8997 8963 8704 8572 9529
Most deprived quintile 575 582 522 530 2209 1933 276
60.1% 56.9% 54.8% 55.5% 56.8% 57.6% 51.7%
ARLD code in primaryb  480 550 508 463 2001 1636 365
50.2% 53.8% 53.3% 48.5% 51.5% 48.8% 68.4%
Short stay (<2 d) 136 150 117 147 550 492 58
14.2% 14.7% 12.3% 15.4% 14.1% 14.7% 10.9%
HDU and/or ITU 80 68 72 84 304 138 166
8.4% 6.7% 7.6% 8.8% 7.8% 4.1% 31.1%
Charlson Index, Score 0 374 401 313 309 1397 1299 98
39.1% 39.2% 32.8% 32.4% 35.9% 38.7% 18.4%
Charlson Index, Score 1-5 124 140 105 112 481 432 49
13.0% 13.7% 11.0% 11.7% 12.4% 12.9% 9.2%
Charlson Index, Score >5 459 481 535 534 2009 1622 387
48.0% 47.1% 56.1% 55.9% 51.7% 48.4% 72.5%
Acute kidney injury codes 161 191 244 246 842 487 355
16.8% 18.7% 25.6% 25.8% 21.7% 14.5% 66.5%
Ascites codes 298 308 333 320 1259 973 286
31.1% 30.1% 34.9% 33.5% 32.4% 29.0% 53.6%
Varices codes 162 146 139 156 603 513 90
16.9% 14.3% 14.6% 16.3% 15.5% 15.3% 16.9%
Died 123 124 152 135 534 0 534
12.9% 12.1% 15.9% 14.1% 13.7% 0.0 100%
aCounts and percentages unless otherwise stated. 
bSpecific ICD-10 codes for ARLD recorded as the primary diagnosis. 
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potential for measurable improvement. This suggests perfor-
mance was maintained, but neither improved nor deteriorated 
significantly.
To confirm that the “year effect” was specific to the outlier hos-
pitals, we implemented a logistic regression model with all seven 
hospitals with the addition of an interaction term between outlier 
status indicator and year indicators (Table 4c). No association was 
apparent for non-outliers, but there was a significant difference for 
the outlier group.
Finally, in a model containing data for all hospitals for 2017/18 
(Table 3b), there was no significant association between adjusted 
odds of death and being admitted to one of the original outlier hospi-
tals (OR 0.72, 95% CI 0.46-1.15, P = 0.171), in contrast to the findings 
for the pre-intervention year (Table 3a).
3.6 | Comparison of locally collected audit data at 
outlier and non-outlier group of hospitals
Modifications to the number and definitions of process measures 
over the course of the AQ initiative precluded a robust analysis 
of serial trends for individual measures. However, at the time of 
initiation of the programme, as a group the outlier hospitals had 
significantly lower performance than the non-outlier group in 5 
of an original set of 11 process measures (46%), Table 5a. By the 
end of the observation period, there was significantly lower per-
formance in only two of seven revised process measures (29%), 
Table 5b. These data suggest that care processes at outlier hos-
pitals had greater scope for improvement at the start of the pro-
gramme than at the non-outlier group. Furthermore, performance 
differences between the two groups of hospitals reduced over 
time.
The financial incentive scheme (annual CQIN payment linked 
to participation) was taken up by the commissioners of two 
non-outlier and one outlier hospital, suggesting that this fi-
nancial incentive per se was not associated with the successful 
implementation.
F I G U R E  2   Reduction in unexplained variation in mortality for 
index admissions for alcohol-related liver disease (ARLD) between 
2014/2015 and 2017/2018 for seven hospitals in the North West 
region of England that participated in a QI programme. Funnel 
plots of standardised mortality ratio (SMR) for ARLD for the pre-
intervention year (2014/2015) and 3 consecutive years after the start 
of the Advancing Quality programme. In the pre-intervention year 
(A), three of seven hospitals were identified retrospectively as having 
been “outliers” for mortality (standardised mortality ratio [SMR] 
above the upper 98% control limit). There was a stepwise reduction 
in the number of outliers over time, with none persisting by the 
final year (D). Dotted lines represent the 95% (5% significance) and 
98% (2% significance) control limits. SMR is plotted against number 
of index admissions. (A) Pre-intervention (2014/2015). (B) Post-
intervention, first year (2015/2016). (C) Post-intervention, second 
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3.7 | Performance of outliers and non-outliers on 
publicly available all-cause mortality statistics
We compared our findings for ARLD-specific mortality with 
publicly available statistics for all-cause hospital mortality for 
2014/2015, based on the SHMI indicator.22 Only one of the three 
outlier hospitals for ARLD mortality from our models had a SHMI 
above the national upper limit and none of the non-outlier hospi-
tals. Hence, our “outlier” hospitals for ARLD mortality in the pre-
intervention year were not identifiable as a group of providers that 
had a general pattern of unexplained all-cause mortality in rou-
tinely published statistics. This suggests our findings are relevant 
to acute care for ARLD rather than reflective of more generic in-
stitutional factors.
4  | DISCUSSION
To our knowledge this is the first study to demonstrate a reduction 
in unexplained variation in hospital mortality for ARLD associated 
Variablea 
Adjusted odds ratio 
(OR) 95% CI P-value
(a) Pre-intervention year (2014/2015)
Admitted to outlier hospitalb  2.13 1.32-3.44 0.002
Acute Kidney Injury codes 10.33 6.37-16.77 <0.001
HDU and/or ITU 9.55 5.12-17.79 <0.001
ARLD code in primary 4.16 2.46-7.05 <0.001
Age group (y)
18-39 (reference group) Ref. Ref. Ref.
40-49 1.23 0.43-3.56 0.697
50-59 3.02 1.10-8.27 0.032
60-69 3.69 1.33-10.24 0.012
70 and above 3.95 1.24-12.55 0.020
(b) Post-intervention year (2017/2018)
Admitted to outlier hospitalb  0.72 0.46-1.15 0.171
Acute Kidney Injury codes 8.89 5.70-13.88 <0.001
HDU and/or ITU 3.91 2.25-6.80 <0.001
Ascites 1.81 1.17-2.80 0.007
Charlson index category
0 (reference group) Ref. Ref. Ref.
1-5 1.54 0.66-3.61 0.319
>5 2.31 1.32-4.05 0.004
aOnly retained variables in stepwise logistic regression models are shown. See text for full list of 
variables. 
bOutlier status was determined by identifying hospitals with a standardised mortality ratio (SMR) 
lying above the 3 SD upper control limit in the pre-intervention year (2014/2015), as shown in 
funnel plot (Figure 2A). Three hospitals were outliers. 
TA B L E  3   Association between 
admission to an original outlier hospital 
and case mix adjusted odds of inpatient 
death in 2014/2015 (pre-intervention) 
and 2017/2018 (post-intervention). 
(a) In 2014/2015, admission to an 
“outlier” hospital was confirmed to 
be independently associated with an 
increased odds of inpatient death for 
alcohol-related liver disease; (b) By 
2017/2018, admission to one of the 
original outlier hospitals was no longer 
associated with an increased odds of 
death
F I G U R E  3   Comparison of case mix adjusted mortality for index 
admissions for alcohol-related liver disease (ARLD) to each of seven 
hospitals in 2014/2015 (pre-intervention) and 2017/2018 (post-
intervention). Bars indicate standardised mortality ratios (SMRs). 
Asterisk identifies the three hospitals with an SMR above the three 
SD control limit in 2014/2015, designated “outliers”
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with a QI programme. We began by determining whether there had 
been “unexplained” variation in mortality between hospitals prior 
to the intervention, confirming a number of outliers. As a group, 
the outlier hospitals had significantly poorer performance on 5 of 
11 AQ measures (46%) at the start of the programme. Our analyses 
of independent administrative data showed that the adjusted odds 
of death for index cases admitted to “outlier” hospitals was signifi-
cantly higher in the year before the AQ intervention (twofold). We 
were able to show that institutional performance improved over 
time, as reflected by elimination of mortality outliers following roll-
out of the QI programme. The adjusted odds of death in post-inter-
vention years was reduced compared to the pre-intervention year at 
outlier hospitals, but it remained unchanged for the other hospitals. 
Although the number and definitions of local AQ measures evolved 
over the course of the programme, the original outlier group had 
lower performance in only two of seven care process metrics (29%) 
by the end of the observation period.
Variation in acute care quality for cirrhosis has been highlighted 
in other countries with proposals on a wide range of metrics to sup-
port QI,10,7,11,8,12 but there has been frustratingly little evidence pub-
lished to show whether reductions in avoidable hospital mortality 
can be achieved.14 The original panel of measures in the North West 
AQ programme contained elements of the recently endorsed “liver 
bundle”,26,27 and formal completion of a local bundle proforma was 
one of the AQ measures. Rates of completion of bundle documen-
tation at our hospitals were relatively low, compared with metrics of 
specific processes. Further research is needed to identify the opti-
mum bundle of interventions, quality metrics and implementation 
models needed to achieve sustained, service-wide reductions in 
avoidable inpatient deaths during the acute phase of care.
Our study has a number of strengths. Rather than focusing on 
data captured for samples of cases included in periodic local au-
dits, we used administrative data as it is independent of the audit 
process and allows unbiased case ascertainment over a continuous 
observation period. By including a sample of hospitals with signifi-
cant variation in baseline performance for mortality, our evaluation 
was able to explore trends for hospitals with, and without, outlying 
performance.
We applied clinically informed methods for interrogating admin-
istrative data. Lack of credibility for simplistic analyses of discharge 
coding among front-line teams has led to calls for better approaches 
to using administrative data to capture hospital activity for alco-
hol-related conditions.28 We confirmed that for ARLD it was nec-
essary to improve on the traditional “primary diagnosis” approach 
for cohort identification, developing a novel clinically designed al-
gorithm to reflect the complexity of clinical presentations and re-
al-world coding practice.
Although modest in scale, our validation against local hospital 
records showed clear evidence for incomplete case identification 
with the traditional approach (sensitivity just 61.5%) and the mer-
its of an algorithmic approach. Routine statistics based on primary 
TA B L E  4   Association between fiscal year of admission and 
case mix adjusted odds of inpatient death for the outlier group and 
non-outlier group of hospitals. (a) Compared to the pre-intervention 
year, adjusted odds of death for index admissions for alcohol-
related liver disease (ARLD) was significantly reduced in post-
intervention years 2015/2016 and 2017/2018 at outlier hospitals. 
(b) There was no significant association between year of admission 
and adjusted mortality at non-outliers. (c) A model containing all 
seven hospitals confirmed that a significant “year effect” was only 
apparent at the original outlier group of hospitals
Financial year of 
admission
Adjusted odds 
ratioa  (OR) 95% CI P-value


























(c) Model containing outlier and non-outlier group (n = 7 hospitals)


























aLogistic regression models include age group, sex, Charlson co-
morbidity index, deprivation status, ARLD coded as primary diagnosis, 
short stay, high dependency unit (HDU) and/or intensive therapy unit 
(ITU) care, codes for acute kidney injury, ascites and varices. 
bThis model includes an interaction between outlier status and year. 






(a) Original set of 11 quality measures at the start of the programme (2015/2016)
ARLD-01 Early warning score recorded within 60 min 
of hospital arrivala 
86.2 74.5 0.143
ARLD-02 Alcohol misuse screening within 4 h of 
hospital arrivalb 
89.3 72.2 0.002
ARLD-03 Antibiotics and Terlipressin within 4 h of 
suspected variceal bleed
77.8 17.9 <0.001
ARLD-04 IV Pabrinexc  within 6 h of hospital arrival 54.5 36.0 <0.001
ARLD-05 Blood tests results available within 4 h of 
hospital arrival
90.7 89.6 0.162
ARLD-06 Ascitic tap performed within 8 h of 
hospital arrival
52.3 35.8 0.047
ARLD-07 Gastroenterology or Hepatology ward 
admission or specialist review within 48 h 
of hospital arrival
70.8 71.4 0.701
ARLD-08 Patient seen by or referred to alcohol 
services prior to dischargeb 
77.1 53.2 0.072
ARLD-09 Risk of alcohol withdrawal assessed within 
4 h of hospital arrivald 
44.7 22.3 0.143
ARLD-10 Care bundle commenced within 4 h of 
hospital arrivale 
28.5 20.1 0.704
ARLD-11 Serum lactate taken within 3 h of hospital 
arrivalf 
28.0 10.4 0.045
b. Revised Set of Seven Quality Measures (2017/2018)
ARLD-12 Alcohol screen and referral to Alcohol Care 
Team within 24 h of hospital arrivalb 
74.8 72.2 0.568
ARLD-13 Risk of alcohol withdrawal assessed within 
4 h of hospital arrivald 
52.6 20.6 0.054
ARLD-14 Antibiotics and terlipressin within 4 h of 
senior review documentation of suspected 
variceal bleed
78.6 83.3 1.000
ARLD-15 IV Pabrinex within 6 h of hospital arrivalc  57.5 56.4 0.545
ARLD-16 Ascitic tap performed within 8 h of senior 
review documentation to tap
96.4 33.3 0.001
ARLD-17 Gastroenterology or Hepatology ward 
admission or specialist review within 48 h 
of hospital arrival
88.8 69.4 0.180
ARLD-18 Care bundle utilised during patient hospital 
staye 
27.2 0.0 <0.001
Note: Further details of the AQ metrics are available on request: advancing.quality@nhs.net
aARLD-01 (baseline nursing observations used to calculate the local “Early Warning Score”) was 
retired in the revised set as performance for this generic process measure was consistently high at 
all hospitals. 
bARLD-02 and -08 were merged into one measure, ARLD-12, in the revised set. “Screening” refers 
to documentation of answers to at least one of three screening questions for alcohol excess. 
cPabrinex = Intravenous High Potency, Concentrate for Solution for Infusion (Vitamin B1) (Kyowa 
Kirin Ltd). 
dRisk of alcohol withdrawal required the documentation of a validated risk score (eg the AUDIT-C 
or CAGE screening tools). 
e“Care bundle” was any locally approved decision-support document that outlined the AQ 
measures and was completed for the individual patient and available in the case records. 
fARLD-11 was retired as it was considered more relevant to sepsis pathways than ARLD per se. 
TA B L E  5   Local audit data for the 
Advancing Quality (AQ) process metricsa, 
comparing pooled data for the “outlier” 
and “non-outlier” group of hospitals. 
Significant differences in performance 
between the two groups on individual 
metrics are highlighted in bold text
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diagnosis alone may miss almost 40% of true admissions for ARLD, 
seriously under-estimating burden and risking the generation of 
misleading metrics. We focused specifically on index admissions 
to identify a fixed point in the care pathway and establish a more 
level playing field for institutional comparisons.
Further evidence for face validity of our cohort identification 
method is provided by comparing the characteristics of patients 
who died to that of the national sample of inpatient deaths reviewed 
by NCEPOD.4 In that report, 20% of ARLD deaths occurred within 
72 hours of admission (vs 22% in our study), mean age was 58 years (as 
in our study), gastrointestinal bleeding in 20.7% (vs 17% with varices 
codes) and ascites in 55.7% (vs 54% with relevant codes). The NCEPOD 
review only reported “established renal failure at presentation,” but 
this was highly prevalent at 30% for those dying during admission (vs 
66% with codes for acute kidney injury among deaths in our study). A 
recent study of people who died from liver disease in England identi-
fied renal complications as strongly associated with hospital death.29
We focused deliberately on in-hospital mortality during index 
admissions as we believe this metric was of most relevance to the 
potential impact of the QI programme. The AQ measures were tar-
geting the essential elements of acute hospital care in the early days 
of an emergency admission. We did not study post-discharge or 
longer term mortality, as these outcomes would be influenced by 
subsequent ambulatory hospital aftercare (eg liver clinics) and com-
munity-based alcohol services.
Our analysis of in-hospital mortality moved beyond simple 
generic risk-adjustment variables (age, gender, co-morbidity 
index, deprivation status) to include condition-specific case mix 
factors associated with liver disease severity and complications. 
Sensitivity analyses explored models with alternative sets of vari-
ables to illustrate which factors were independently associated 
with mortality and to optimise final models. Compared to a sim-
ple, generic approach (pseudo-R2 was just 5.5%), the proportion 
of mortality variation explained by the final model was sixfold 
greater (pseudo-R2, 30.7%). This suggests our condition-specific 
case mix factors were relevant surrogates for patient factors as-
sociated with death.
We propose that our methodology for analysing inpatient mor-
tality for index ARLD admissions from administrative data could 
be adopted nationally, helping to identify potentially unexplained 
variation in outcomes of care at a key point in the care pathway. 
This would support targeted reviews of service provision, organi-
sation and care process—complimenting recent efforts to encour-
age formal accreditation of units under the Improving Quality in 
Liver Services (IQILS) programme.30 By focusing on deaths during 
index admissions we have concentrated on acute secondary care 
for first admissions for ARLD, rather than the common approach of 
pooling together both admissions and remissions to generate “ad-
mission-level” mortality metrics that can be difficult to interpret.
This evaluation has a number of limitations. We cannot determine 
cause and effect from an uncontrolled observational study, and the 
temporal trends observed could have been driven by factors external 
to the QI programme. However, this does not negate the evidence 
presented for a narrowing of inter-institutional variation and a se-
lective reduction in mortality risk at those hospitals that began the 
period as “outliers.” This is good news for patients, regardless of 
precise mechanism. Our data suggest that it is, indeed, possible for 
hospitals to achieve reductions in potentially avoidable mortality for 
ARLD. The reasons for this improvement will be complex and multi-
factorial, but we believe it is reasonable to infer an impact of the QI 
programme.
General secular trends in population characteristics or health 
service improvements would not be expected to operate selectively 
at the three “outlier” hospitals and create no signals at the others. 
Our review of publicly available metrics of hospital mortality re-
vealed just one of the seven hospitals had “higher than expected” 
all-cause inpatient mortality in 2014/2015 (only one of the three 
“outliers” for ARLD mortality). This suggests our observations are 
condition specific rather than mirroring general trends of mortality 
at these hospitals.
There are well-known limitations to discharge coding data, in-
cluding potential variations or inaccuracies and a lack of granular 
clinical information for case mix or laboratory data to allow true 
assessment of disease severity. However, the aim of our work was 
to develop better ways to use currently available administrative 
datasets to study outcomes of hospital care. It is hoped that future 
progress with structured electronic health records will enhance 
the opportunities for continuous monitoring of risk-adjusted out-
comes at regional or national scales, with access to richer clinical 
variables such as laboratory parameters of liver disease severity. 
However, for the time being we propose our methods could be 
applied to national administrative datasets to identify variation 
and support nationwide programmes focused on improving acute 
hospital care for ARLD. We have not attempted to compare char-
acteristics of individual hospital services or to draw inferences 
about local factors associated with “outlier” status. Our aim was 
to establish that variation in mortality between providers was 
present before the QI programme started and that it reduced 
afterwards.
5  | CONCLUSIONS
This study challenges the pessimism and therapeutic nihilism that 
is prevalent for this vulnerable group of “hard-to-help” patients.31 
Lack of progress in policies for prevention has been highlighted 
recently,32 emphasising the ongoing need to optimise acute ser-
vices to deal with the ongoing demands for emergency liver and 
alcohol care. Notwithstanding the well-known limitations of an 
uncontrolled observational study, these data provide hope that 
co-ordinated efforts to drive adoption of evidence-based practice 
for acute care of ARLD can save lives. Further research is needed 
to identify the optimum bundle of interventions, quality metrics 
and implementation models needed to achieve sustained, service-
wide reductions in avoidable inpatient deaths in the acute phase 
of care.
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